Science Exchange (company)

Last updated
Science Exchange
Company type Private
IndustrySoftware
SaaS
Biotechnology
Founded2011
Founders Elizabeth Iorns, Dan Knox, Ryan Abbott
Headquarters
Palo Alto, California
,
U.S.
Key people
 Elizabeth Iorns (Co-Founder & CEO)
Dan Knox (Co-Founder & COO)
Tzlil Hadass (CRO)
Number of employees
93 (Jun 2022) [1]
Website scienceexchange.com

Science Exchange is a cloud-based software company offering an R&D marketplace to buy and sell scientific services. [2] [3] [4] The marketplace gives life sciences companies access to the outsourced research they need and the platform fully automates R&D outsourcing from source to pay. [4] [5] Commercial contract research organizations (CROs) and academic core facilities can sell their products and services directly through the marketplace.

Contents

Science Exchange's enterprise clients include top pharma and emerging biotechnology companies, including Merck, Amgen, Gilead Sciences, Astellas Pharma, AbbVie, and Regeneron Pharmaceuticals. [6]

Science Exchange was founded in 2011 by Elizabeth Iorns, Ryan Abbott, and Dan Knox, taking part in the startup accelerator program Y Combinator in the summer of 2011. [2] [3] [7] [8]

History

In 2011, while an Assistant Professor at the University of Miami Miller School of Medicine, Iorns came up with the idea for Science Exchange after needing to conduct immunology experiments, but having difficulty finding potential collaborators or providers to work with. [9] [10] Iorns formed Science Exchange with Knox and Abbott, and the company applied for a place in the Y Combinator startup accelerator program. [8] The company was accepted into the Summer 2011 batch of Y Combinator and launched the first version of its website in August 2011. [8] In 2012 Iorns was recognized by the Kauffman Foundation for her role in starting Science Exchange. [11] [12] [13]

Business model

Science Exchange is a Software-as-a-Service (SaaS), with customers paying an annual subscription fee.

Projects

Reproducibility initiative

In August 2012 Science Exchange partnered with the open-access scientific publisher Public Library of Science (PLOS) to launch the Reproducibility Initiative, a program developed to assist researchers in validating their findings by repeating their experiments through independent laboratories. [2] [14] [15] The program is facilitated by the Science Exchange platform, which matches scientists with experimental service providers according to areas of expertise. Iorns has been a longtime spokesperson on the issue of reproducibility in academic research. [13] [16]

In 2013 Science Exchange partnered with the Center for Open Science to reproduce findings from widely cited published research in the field of cancer research. The goal of the study, called the Reproducibility Project: Cancer Biology (RP:CB), is to find common reasons explaining why aspects of experiments are hard to reproduce by independent laboratories. [17] [18] [19] In January 2017, the first five replication studies of the Reproducibility Project: Cancer Biology (RP:CB) were published. [20] Three more RP:CB replication studies were published in June 2017. [21]

Independent validation program

On 30 July 2013 Science Exchange launched a program with reagent supplier antibodies-online.com, based in Aachen, Germany, to independently validate research antibodies. [22] [23] [24]

Investors

In June 2011, Science Exchange received a $100,000 investment from StartFunds' Yuri Milner, a $50,000 investment from angel investor Ron Conway, and a $20,000 investment from Y Combinator as part of participating in the startup accelerator program. In December 2011 the company announced it had closed a $1.5-million seed financing round led by Andreessen Horowitz. [3] [7] [8] [25] [26] In May 2013 the company closed a $4-million Series A financing round led by Union Square Ventures, Tim O'Reilly's O'Reilly AlphaTech Ventures and several leading angel investors including Esther Dyson, Joshua Schachter, Lisa Gansky and Yuri Milner. [27] [28] [29] [30] In March 2016 the company announced it had closed a $25-million Series B financing round led by Lee Ainslie's Maverick Capital. [31] In June 2017 Science Exchange raised $28-million in Series C funding, led by Norwest Venture Partners. In October 2019, the company announced it had raised an additional $20 million in financing, from a combination of equity and debt sources. Maverick Ventures and Norwest Venture Partners led the financing. [32]

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

<span class="mw-page-title-main">Exelixis</span> American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

<span class="mw-page-title-main">Y Combinator</span> American startup accelerator

Y Combinator Management, LLC (YC) is an American technology startup accelerator and venture capital firm launched in March 2005 which has been used to launch more than 4,000 companies. The accelerator program started in Boston and Mountain View, expanded to San Francisco in 2019, and was entirely online during the COVID-19 pandemic. Companies started via Y Combinator include Airbnb, Coinbase, Cruise, DoorDash, Dropbox, Instacart, Reddit, Stripe, and Twitch.

Justin Kan is an American internet entrepreneur and investor. He is the co-founder of live video platforms Justin.tv and Twitch, as well as the mobile social video application Socialcam. He is also the cofounder and former CEO of law-tech company Atrium. In 2024, Kan announced that he had founded Stash, a payment and e-commerce platform for video game developers.

Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies.

Startup accelerators, also known as seed accelerators, are fixed-term, cohort-based programs, that include mentorship and educational components, and culminate in a public pitch event or demo day. While traditional business incubators are often government-funded, generally take no equity, and rarely provide funding, accelerators can be either privately or publicly funded and cover a wide range of industries. Unlike business incubators, the application process for seed accelerators is open to anyone, but is highly competitive. There are specific accelerators, such as corporate accelerators, which are often subsidiaries or programs of larger corporations that act like seed accelerators.

<span class="mw-page-title-main">Galena Biopharma</span> American pharmaceutical company

Galena Biopharma was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc.

Elizabeth Jane Iorns is a New Zealand scientist, entrepreneur and researcher, and the founder and CEO of Science Exchange, a Silicon Valley startup which operates a platform to allow scientists to outsource their research to scientific institutions such as university facilities or commercial contract research organizations. Science Exchange has received considerable media attention since it first launched in August 2011, particularly following its participation in the Y Combinator incubator program in Summer 2011 and its role in launching the Reproducibility Initiative in Summer 2012. Iorns has been profiled in many leading publications including Nature, FastCompany, the San Francisco Business Times and Xconomy. Iorns lives in Palo Alto, California, where Science Exchange is now headquartered.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

<span class="mw-page-title-main">StartX</span> US non-profit startup accelerator

StartX is a non-profit startup accelerator and founder community associated with Stanford University.

Two River Group Holdings is a New York-based venture capital firm and merchant bank focused on the life science sector. It specializes in investments in life science, biotechnology, and in firms focused on developing preventive and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.

Intersect ENT, a subsidiary of Medtronic, is a health care equipment company based in Menlo Park, California. It manufactures drug-delivery devices used by Ear, Nose & Throat (ENT) clinicians in the treatment of sinusitis. Intersect ENT is best known for developing the first bioabsorbable drug-eluting sinus stent PROPEL, which delivers anti-inflammatory medication directly to the sinuses. The company holds over 20 issued patents in the United States and more than 80 patents and patent applications worldwide. The company was named on the Forbes list of America's Most Promising Companies and was also on the Fierce 15 list of Most Promising Companies in 2013.

<span class="mw-page-title-main">Acceleron Pharma</span> American healthcare company

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Kite Pharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically engineered autologous CAR T cell therapy, a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.

Foundation Medicine, Inc. is an American company based in Cambridge, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.

Bikanta is a startup biotech company that develops clinical products which focuses on the detection of cancer through the insertion of fluorescent nanodiamonds. The company was founded by Ambika Bumb as a solution to combat the inadequacies of cancer screening technology. Bikanta currently has a five-member board of advisors that aid in nanodiamond industry research.

<span class="mw-page-title-main">Scientist.com (company)</span> Network of e-commerce marketplaces

Scientist.com is a network of public and private e-commerce marketplaces that connect buyers and sellers of scientific research services. The company was founded in 2007 by Kevin Lustig, Chris Petersen and Andrew Martin and launched its first public research marketplace in September 2008.

References

  1. ↑ https://www.linkedin.com/company/2306727/ [ self-published source ]
  2. 1 2 3 Sharon Begley (14 August 2012), More trial, less error: An effort to improve scientific studies, Reuters, retrieved 18 August 2012
  3. 1 2 3 "MixRank, Favo.rs, Science Exchange, Sprintly", Financial Post, 7 December 2011, retrieved 18 August 2012
  4. 1 2 Bernadette Tansey (30 June 2017), As Big Pharma Flocks to Science Exchange, Norwest Leads $28M Funding, Xconomy, retrieved 29 Jan 2018
  5. ↑ Alex Konrad (29 June 2017), "Science Exchange Takes On $28M To Help Companies Outsource R&D", Forbes, retrieved 29 Jan 2018
  6. ↑ Mark Brohan (25 March 2024), A B2B marketplace from Science Exchange aims to make life easier for buyers, Digital Commerce 360, retrieved 5 April 2024
  7. 1 2 Ron Leuty (2 September 2011), Market for Science, San Francisco Business Times, retrieved 18 August 2012
  8. 1 2 3 4 Jason Kincaid (16 August 2011), YC-Funded Science Exchange: A Central Marketplace For Core Research Facilities, TechCrunch, retrieved 18 August 2012
  9. ↑ Zoë Corbyn (19 August 2011), "An eBay for Science", Nature, doi: 10.1038/news.2011.492 , retrieved 18 August 2012
  10. ↑ Leading a Movement to Change the Pace of Scientific Research, Scientific American, 2 April 2012, retrieved 18 August 2012
  11. ↑ 2012 Kauffman Foundation Postdoctoral Entrepreneur Awards Recognize Entrepreneurship Excellence in Researchers, Kauffman Foundation, 14 March 2012, retrieved 18 August 2012
  12. ↑ Ron Leuty (27 April 2012), One-on-one with Science Exchange's Elizabeth Iorns, San Francisco Business Times, retrieved 18 August 2012
  13. 1 2 David Zax (4 April 2012), Dropping Some Science: Scientists, Ditch The Academy And Become Entrepreneurs, Fast Company, retrieved 18 August 2012
  14. ↑ Carl Zimmer (14 August 2012), Good Scientist! You Get a Badge, Slate, retrieved 18 August 2012
  15. ↑ Reproducibility Initiative to Increase the Value of Biomedical Research, Bio IT World, 17 August 2012, retrieved 18 August 2012
  16. ↑ Elizabeth Iorns (6 April 2012), The Need for Reproducibility in Academic Research, Science Exchange, retrieved 18 August 2012
  17. ↑ Ed Yong (18 January 2017), How Reliable Are Cancer Studies?, The Atlantic, retrieved 22 February 2017
  18. ↑ Nature editorial (18 January 2017), "Replication studies offer much more than technical details", Nature, 541 (7637): 259–260, Bibcode:2017Natur.541R.259., doi: 10.1038/541259b , PMID   28102281, S2CID   4452092 , retrieved 22 February 2017
  19. ↑ Belluz, Julia (23 January 2017), Cancer scientists are having trouble replicating groundbreaking research, Vox, retrieved 22 February 2017
  20. ↑ Richard Harris (18 January 2017), What Does it Mean When Cancer Findings Can't Be Reproduced?, NPR, retrieved 22 February 2017
  21. ↑ Open Science Framework (27 June 2017), Reproducibility Project:Cancer Biology page on the Open Science Framework, Open Science Framework, doi:10.17605/OSF.IO/E81XL , retrieved 3 December 2017
  22. ↑ Meredith Wadman (31 July 2013), "NIH mulls rules for validating key results", Nature, 500 (7460): 14–16, Bibcode:2013Natur.500...14W, doi: 10.1038/500014a , PMID   23903729, S2CID   321809
  23. ↑ Nicola Kurth (March 23, 2014). "Rettet die Wissenschaft". Spiegel Online. Retrieved September 26, 2014.
  24. ↑ Jeffrey M. Perkel (March 2014). "The Antibody challenge". BioTechniques. Retrieved September 29, 2014.
  25. ↑ Jason Kincaid (2 December 2011), Science Exchange's Marketplace For Research Facilities Gets A $1.5 Million Boost, TechCrunch, retrieved 18 August 2012
  26. ↑ Ron Leuty (5 December 2011), Science Exchange Raises $1.5 M, San Francisco Business Times, retrieved 18 August 2012
  27. ↑ Peter Kafka (29 April 2013), Science Exchange Raises $3 Million to Help Outsource Experiments, AllThingsD, retrieved 3 May 2013
  28. ↑ Andy Weissman (29 April 2013), Science Exchange, USV, retrieved 3 May 2013
  29. ↑ Bryce Roberts (29 April 2013), Our Investment in Science Exchange, OATV, retrieved 3 May 2013
  30. ↑ Science Exchange (30 April 2013), Science Exchange Series A Financing, Science Exchange, retrieved 3 May 2013
  31. ↑ Sarah Buhr (23 March 2016), Science Exchange moves into big pharma with $25 million in Series B funding, TechCrunch, retrieved 30 March 2016
  32. ↑ "Science Exchange Raises Capital to Advance Innovative Outsourced R&D Platform to Drive Biopharma Productivity". www.businesswire.com. 2019-10-16. Retrieved 2019-10-17.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.